Loading…
US Pharmaceuticals Inc. received an FDA Warning Letter on June 6, 2019, regarding drug products, though the specific violations and issuing office details are not available in the metadata provided. Without access to the full letter text or subject line, the exact nature of the compliance issues cannot be determined from this summary information alone. This warning relates to the company's drug manufacturing, marketing, or distribution practices under FDA jurisdiction. Additional documentation would be needed to identify the specific regulatory violations and required corrective actions.